Translating academic
research into
new medicines

The Queensland Emory Drug Discovery Initiative (QEDDI) is a small molecule drug discovery and development group dedicated to translating academic biomedical research into new medicines.

QEDDI is a business unit of UniQuest and the only example of its kind in an Australian university. QEDDI has an industry-experienced team dedicated to advancing biomedical research into new drug candidates to enable commercial partnerships and accelerate new drug development.

Project pipeline

QEDDI’s pipeline includes new treatments for unmet medical needs, including cancer, inflammatory disorders and neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease.

QEDDI Uniquest Queensland Emory Drug Discovery Initiative

our capabilities

QEDDI has capabilities and expertise to carry out the key phases in a drug discovery program.
QEDDI Uniquest Queensland Emory Drug Discovery Initiative

Hit identification

Identification of lead-like small molecule hits for a specific biological target. QEDDI are partners in the Australian Lead ID Consortium (ALIDC).

QEDDI Uniquest Queensland Emory Drug Discovery Initiative

Rational design

Structure-activity-relationship (SAR) development using rational and structure-guided drug design to support hit-to-lead and lead optimisation medicinal chemistry.

QEDDI Uniquest Queensland Emory Drug Discovery Initiative

Lead optimisation

Iterative compound optimisation to achieve the desired efficacy, safety and DMPK profile in a preclinical development candidate.

latest news

New target to beat cancer drug resistance

New target to beat cancer drug resistance

University of Queensland researchers have identified a novel drug target with the potential to overcome drug resistance and prevent tumour regrowth in cancer patients.
Associate Professor Helmut Schaider from UQ’s Frazer Institute said the newly identified molecule was not currently a target for treatment, opening the potential for drug development.

read more